



Published in final edited form as:

*Gynecol Oncol.* 2019 April ; 153(1): 116–122. doi:10.1016/j.ygyno.2019.01.017.

## Breastfeeding factors and risk of epithelial ovarian cancer

**Francesmary MODUGNO, MS, PhD, MPH,**

Womens Cancer Research Program, Magee-Womens Research Institute and UPMC Hillman Cancer Center, and Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA USA

**Sharon L. GOUGHNOUR, MPH,**

Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA USA

**Danielle WALLACK, MPH,**

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA USA

**Robert P. EDWARDS, MD,**

Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA USA

**Kunle ODUNSI, MD,**

Roswell Park Cancer Institute, Buffalo, NY USA

**Joseph L. KELLEY, MD,**

Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA USA

**Kirsten MOYSICH, PhD,**

Roswell Park Cancer Institute, Buffalo, NY USA

---

**Corresponding Author:** Francesmary Modugno, PhD, MPH, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Suite 2130, 300 Halket Street, Pittsburgh, PA 15213 (412) 641 5418 (ph); (412) 641 5417 (fax), modugno@upmc.edu; fm@cs.cmu.edu.

### AUTHOR CONTRIBUTIONS

Francesmary Modugno: Contributed to the conception and design of the study, analysis, and interpretation of data, drafted the article, and approved the final version submitted for publication.

Sharon L. Goughnour: Contributed to the analysis and interpretation of data, revision of the article, and approved the final version submitted for publication.

Danielle Wallack: Contributed to the analysis and interpretation of data, revision of the article, and approved the final version submitted for publication.

Robert P. Edwards: Contributed to the collection of study data, revision of the article, and approved the final version submitted for publication.

Kunle Odunsi: Contributed to the collection of study data, revision of the article, and approved the final version submitted for publication.

Joseph L. Kelly: Contributed to the collection of study data, revision of the article, and approved the final version submitted for publication.

Kirsten Moysich: Contributed to the collection of study data, conception and design of the study, revision of the article, and approved the final version submitted for publication.

Roberta B. Ness, MD: Contributed to the collection of study data, conception and design of the study, revision of the article, and approved the final version submitted for publication.

Maria Mori Brooks: Contributed to the analysis and interpretation of data, revision of the article, and approved the final version submitted for publication.

### CONFLICT OF INTEREST

The authors report no conflicts of interest.

**Roberta B. NESS, MD**, and

University of Texas School of Public Health, Houston, TX USA

**Maria Mori BROOKS, PhD**

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health,  
Pittsburgh, PA USA

## Abstract

**Objective:** Previous studies suggest that breastfeeding protects against epithelial ovarian cancer (EOC). However, the effects of age, timing and episode details on the EOC-breastfeeding relationship have not been examined. The objective of this study was to examine the association between breastfeeding factors and epithelial ovarian cancer.

**Methods:** We examined breastfeeding factors among parous women in a population-based, case-control study conducted in Pennsylvania, Ohio, and New York from 2003–2008. We compared 689 incident EOC cases to 1572 community controls. Multivariable unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) associated with breastfeeding patterns adjusting for potential confounders.

**Results:** Compared to never breastfeeding, breastfeeding any offspring was associated with a 30% reduction in EOC risk (OR=0.70; 95% CI=0.58–0.85). That protection lasted more than 30 years (OR=0.69, 95% CI=0.53–0.88). An average breastfeeding episode of months provided significant protection (OR=0.75, 95% CI=0.61–0.94). Greater number of breastfeeding episodes increased protection (OR=0.78, 95% CI=0.64–0.96 and OR=0.49, 95% CI=0.36–0.68 1–2 and 3+ episodes, respectively, compared to never breastfed, trend p=0.01). Longer breastfeeding duration also increased protection (OR=0.75 and 0.62 for less than and greater than 1-year total duration, respectively, compared to never breastfed). An earlier age at first breastfeeding was also more protective (OR=0.63, 0.71, 0.92, for first episode at age <25, 25–29, and 30+, respectively, trend p=0.001).

**Conclusions:** Breastfeeding for as few as 3 months protects against EOC. Although this protection decreases over time, it persists for more than 30 years. Longer cumulative duration, increasing number of breastfeeding episodes, and earlier age at first breastfeeding episode increase protection.

## Keywords

Breastfeeding; Epithelial Ovarian Cancer; Case-Control Study; Epithelial Ovarian Cancer

## INTRODUCTION

Ovarian cancer is the most lethal gynecologic malignancy.<sup>1</sup> In 2018, approximately 22,240 women in the United States will be diagnosed with the disease and over 14,000 women will die from it.<sup>1</sup> When diagnosed at an early stage, 5-year survival is more than 90%.<sup>1</sup> Unfortunately, more than 70% of cases are diagnosed at a late stage, when 5-year survival is less than 30%.<sup>1</sup> This high fatality rate, coupled with the lack of a screening test for early detection,<sup>2</sup> makes it critical to identify modifiable risk factors to reduce disease burden.<sup>3</sup>

Oral contraceptive (OC) use and bearing children have consistently been shown to reduce the risk of epithelial ovarian cancer (EOC), which accounts for 90% of ovarian cancers<sup>4</sup> and is believed to arise from the ovary or fallopian tubes.<sup>5</sup> Each factor is associated with about a 30% decrease in risk, with greater protection conferred by increasing duration of OC use<sup>6</sup> and greater parity.<sup>7</sup> Although attenuated somewhat, the protection afforded by OCs persists for more than 30 years.<sup>6</sup> A similarly durable, but somewhat attenuated protective effect remains after the last live birth.<sup>8</sup> OC use and child bearing are hypothesized to reduce risk via several ways, although the exact mechanisms remain unknown. Both factors suppress ovulation, thereby reducing repetitive trauma to ovarian surface or tubal epithelium that can result in aberrant repair and subsequent malignant transformation.<sup>9,10</sup> Both factors also reduce gonadotropin levels, which result in lower estrogen levels. Estrogen can increase ovarian surface and tubal epithelial proliferation, potentially leading to malignant transformation.<sup>11,12</sup> Finally, pregnancy and OCs alter endogenous estrogen and progesterone levels, two hormones that have been implicated in EOC risk.<sup>13</sup>

Breastfeeding also suppresses ovulation, reduces gonadotropin levels, and alters the hormonal milieu<sup>14</sup>; thus, it may protect against EOC. Most case-control studies report a protective effect with ever breastfeeding.<sup>7,15,16</sup> Some also report increasing protection with increasing cumulative duration.<sup>7,15,16</sup> In contrast, the handful of cohort studies examining breastfeeding found a weak, non-significant protective effect<sup>15</sup>, except for the Nurses' Health Study, which reported a significant protective effect only after 18 cumulative months of breastfeeding.<sup>17</sup>

Beyond the association with ever breastfeeding and breastfeeding duration, there has been little exploration of factors that may influence the breastfeeding-EOC association. Questions remain about the effects of age at breastfeeding, time since breastfeeding, and influence of birth order among offspring breastfed. We used data from a large, population-based case-control study to examine these questions.

## MATERIAL AND METHODS

### Subjects

Details of the Hormones and Ovarian cancer PrEdiction (HOPE) Study are described elsewhere.<sup>18</sup> Cases were women diagnosed with incident, histologically-confirmed epithelial ovarian, peritoneal, or fallopian tube cancer from February 2003 to November 2008 in the contiguous regions of western Pennsylvania, eastern Ohio, and southwestern New York. Eligible participants were at least 25 years old, residing within the catchment region, and within 9 months of diagnosis at the time of interview. Women were identified through a network of hospital and physician practices using pathology records, physician practice records, and hospital cancer registries. Among 2878 potentially eligible cases, 1,608 were excluded due to ineligibility (time since diagnosis more than 9 months, residence outside catchment region, prior diagnosis of ovarian cancer, inability to speak English, deceased). Of the 1,270 remaining eligible cases, 902 (71%) consented to study participation.

Controls were identified through random-digit dialing and were frequency-matched to cases by 5-year age groups and 3-digit telephone exchange in a 2:1 ratio. Among 3,922 women

screened by phone, 2501 met eligibility requirements, and 1,802 (72%) consented to study participation.

Institutional Review Board approval for the study was obtained from hospitals in which cases were identified and from the University of Pittsburgh. All participants provided written, informed consent.

### Data Collection and Exposure Assessment

Trained interviewers conducted a standardized 2-hour in-person interview to obtain detailed information on reproductive, medical, and demographic data from birth until a reference date. To aid recall, a life events calendar with milestones, such as marriages, births, and deaths, was used.<sup>19</sup> Each pregnancy was denoted on the calendar by coloring the month of pregnancy initiation until pregnancy end. Breastfeeding episodes were similarly noted on the calendar. For each pregnancy, a woman was asked the outcome (live birth, still birth, miscarriage, abortion). For each live birth, she was asked detailed information, including “Did you ever breastfeed this baby?” If she responded “yes”, the total number of months breastfed was elicited by asking “For how many months did you nurse?”

The reference date was calculated as 9 months prior to diagnosis (cases) or interview (controls) to ensure that exposures occurred before ovarian cancer diagnosis in cases and within a similar time frame for controls.

Pathology data were extracted from pathology reports by two independent readers. Differences were reviewed by study staff to assign final pathology data.

### Statistical Analyses

Analyses were limited to the 1,572 controls and 689 cases who reported at least one live birth because nulliparous women are unable to breastfeed a biological child. A woman was classified as having ever breastfed if she indicated ever breastfeeding one offspring. Total duration of breastfeeding was calculated by summing the number of months breastfed across all breastfeeding episodes. Age at first (last) breastfeeding episode was calculated using the month and year of the pregnancy end corresponding to the first (last) breastfeeding episode and the month and year of a subject’s birth. Time since the first (last) breastfeeding episode was obtained by calculating the time elapsed since the end of the first (last) breastfeeding episode until the reference date.

We assessed total number of breastfeeding episodes, breastfeeding some or all offspring, average duration of breastfeeding per breastfeeding episode (defined as total breastfeeding duration divided by total number of offspring breastfed), and the duration of breastfeeding for the first and last breastfeeding episodes.

Case-control differences in demographic and other factors were initially assessed using  $\chi^2$  tests. Multivariable unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between each breastfeeding factor and EOC (separate models for each factor). Age at reference date, total OC duration, parity, race, education, tubal ligation status, hysterectomy status, and family history of breast or

ovarian cancer were selected *a priori* as potential confounders. Family history of breast and ovarian cancer, tubal ligation, and hysterectomy did not affect the relationship between breast feeding and ovarian cancer risk and were not included in the final models. Sensitivity analyses showed estimates were also unchanged by adjusting for age at first live birth, age at last live birth, decade of birth, and year of birth pre vs post 1950. Herein we present the most parsimonious models, which include age at reference date, total OC duration, and parity as continuous variables, and race and education as categorical variables. Tests for trend were performed by coding the exposure of interest as a grouped linear variable. Analyses were repeated examining only women age 50 or over and restricting cases to women with invasive disease only. Further analyses examined the associations limiting to high grade serous EOC (the most common histotype); limited cases of other histotypes precluded meaningful analyses. All *P*-values were two-sided and considered significant at *P* < 0.05. Analyses were conducted using Stata version 9.1 (StataCorp).

## RESULTS

Cases were more likely to be non-white and less educated, as well as to have an increased family history of breast or ovarian cancer (Table 1). They were less likely to have used OCs, borne children, or had a tubal ligation.

Cases were less likely to have breastfed, and breastfeeding was associated with a significant 30% decrease in EOC risk (OR=0.70, 95%CI=0.58–0.85; Table 2). The magnitude of protection was similar whether all (OR=0.71) or only some (OR=0.69) offspring were breastfed, as well as whether the first (OR=0.69) or last (OR=0.72) offspring was breastfed. Greater number of breastfeeding episodes provided increased protection (OR=0.78 and 0.49 for nursing 1–2 and 3+ episodes, respectively, compared to never breastfed, trend *P*=0.01).

Longer total breastfeeding duration across all breastfeeding episodes provided increased protection (OR=0.75 and 0.62 for less than and greater than 1-year total duration, respectively; Table 3). An average duration of 3 months per breastfeeding episode provided significant protection (OR=0.73, 95%CI=0.58–0.93). Longer average duration per breastfeeding episode appeared more protective although the difference was not significant (OR=0.73 and OR=0.67 for 1–3 and 4 or more months average per episode, respectively). Longer duration for both the first (OR=0.75 and OR=0.66 for 1–3 and 4 or more months, respectively) and last (OR=0.76 and OR=0.65) breastfeeding episodes appeared more protective.

An earlier age at first breastfeeding episode was associated with a significant 37% reduction in EOC risk (OR=0.63, 95%CI=0.50–0.80, Table 4). Increasing age at first breastfeeding was associated with a decreasing protective effect (OR=0.63, 0.71, 0.92, for first episode at age <25, 25–29, and 30+, respectively, trend *P*=0.001). In contrast, age at last breastfeeding episode did not have a substantial impact on risk; last breastfeeding episode at any age provided a similar protective effect (OR=0.66, 0.76, 0.70, for last episode at age <25, 25–29, and 30+, respectively).

More recent breastfeeding was associated with a significant 44% reduction in EOC risk (OR=0.56, 95%CI=0.32–0.95 for time since last breastfeeding within the last 10 years, Table 4). Although the protection associated with breastfeeding decreased over time, the effect persisted for more than 30 years after the last breastfeeding episode (OR=0.69, 95%CI=0.53–0.88).

Results were similar when examining women over 50 (Supplemental Tables S1a-c), when restricting cases to women with invasive disease (Supplemental Tables S2a-c), and when restricting cases to high grade serous histotype (Supplemental Tables S3a-c). Number of cases among the other histotypes precluded meaningful analyses.

## DISCUSSION

In the HOPE Study, breastfeeding was associated with a 30% reduction in EOC risk. While this protection decreased over time, it persisted for more than 30 years. Breastfeeding for as little as three months provided significant protection. Longer breastfeeding duration, greater number of breastfeeding episodes, and earlier age at first breastfeeding were each associated with increased protection.

Our results are consistent with the majority of studies that have shown an inverse association between ever breastfeeding and EOC risk. A meta-analysis of 35 studies<sup>16</sup> reported a pooled relative risk of 0.76, which is similar in magnitude to the point estimate (0.70) we report. Data examining the effect of duration are less consistent. Some studies have reported a decrease in risk with increasing total or average duration, whereas others report no trend with increasing duration or no additional benefit from breastfeeding beyond a certain number of months.<sup>17,20–23</sup> Despite reporting inter-study heterogeneity, a recent meta-analysis of 40 studies<sup>15</sup> found a significant point estimate of 0.64 (95%CI 0.56–0.73) for total breastfeeding duration of greater than one year, which is similar to the protective effect we observed (OR=0.62).

Only one previous study explored factors related to age and timing of breastfeeding, with no effects noted.<sup>20</sup> This stands in contrast to our findings in which an earlier age at first breastfeeding episode significantly protected against EOC. That protective effect was evident but decreased with increasing age at first breastfeeding episode. We further found that while more recent breastfeeding imparted greater protection, the protection from breastfeeding persisted for more than 30 years.

A differential effect of age and recency of breastfeeding as well as a persistent effect of exposure are similar to what is observed with OC use.<sup>24</sup> Specifically, as we found for breastfeeding, earlier age at first OC use protects against EOC, with the magnitude of the protective effect decreasing with increasing age at first use.<sup>24</sup> More recent OC use also provides greater protection, and while that protection decreases with time, it remains for more than 30 years after cessation.<sup>24</sup> The impact of age and timing of childbearing on EOC risk is less clear. Recent full-term birth has been associated with a greater decrease in risk in most studies. In contrast to our findings of greater EOC protection with an earlier age at first breastfeeding, a later age at last birth may provide the greatest protection. In particular, age

at last pregnancy has been found to be more critical to EOC risk reduction than number of pregnancies.<sup>8,25,26</sup> This observation is often attributed to the apoptotic effect of high progesterone levels in pregnancy potentially “clearing” premalignant ovarian epithelial cells.<sup>26</sup>

Only one study has examined the pattern of offspring breastfed and its association with EOC, reporting that while breastfeeding in general reduced EOC risk, this protective effect was limited to women who breastfed their last child.<sup>22</sup> We did not replicate that finding. We observed that if breastfeeding any one child provides greater protection, it is the first child, which in our study was associated with a (non-significant) increased protection relative to breastfeeding any child but the first.

A protective effect of breastfeeding is biologically plausible. Although the pathogenesis of EOC remains unclear, two prevailing theories have dominated the literature. The incessant ovulation hypothesis posits that ovulation results in repeated trauma to ovarian surface epithelial cells, and subsequent repair opens the door for malignant transformation. More recently, data suggest that some ovarian cancers may arise from the fimbriated end of the fallopian tube<sup>5</sup>, where release of follicular fluid from ovulation may result in inflammation and DNA damage to tubal epithelial cells.<sup>10</sup> These transformed cells may then migrate and implant on the ovarian surface or within the peritoneal cavity.<sup>27</sup> Regardless of whether EOC arises in the ovary or fallopian tube, factors that decrease ovulation would reduce EOC risk. The gonadotropin hypothesis posits that high levels of gonadotropins increase ovarian estrogen stimulation, thereby promoting ovarian surface and tubal epithelial cell proliferation and increasing the chance for malignant transformation. Thus, factors that decrease gonadotropins would also reduce EOC risk. Breastfeeding suppresses gonadotropins (particularly luteinizing hormone), which reduces estrogen levels and leads to anovulation and amenorrhea.<sup>14</sup> In the absence of breastfeeding, ovulation typically resumes six weeks postpartum, whereas ovulation can be suppressed for several months with lactation.<sup>28,29</sup>

Alterations in the maternal hormonal milieu and/or metabolism are other potential biologic mechanisms whereby breastfeeding may impact EOC risk. Weaning, not birth, is the natural end to a pregnancy episode in terms of pregnancy-associated physiologic changes.<sup>30</sup> Therefore, lactation may reset pregnancy-associated hormonal mechanisms, which could influence EOC risk.<sup>22</sup> It may also reset pregnancy-associated metabolic changes, such as insulin resistance and visceral fat accumulation, that may increase EOC risk.<sup>31,32</sup> Longer breastfeeding duration reduces accumulated fat stores and results in other favorable metabolic changes that persist long after weaning.<sup>31</sup> In contrast, in women who do not breastfeed, adverse metabolic changes associated with EOC risk persist.<sup>30</sup>

A major strength of this study is that it is one of the largest population-based studies of EOC ever conducted in the US. In addition, data were collected through a standardized, structured interview administered by trained personnel, ensuring consistent and high-quality exposure measurements.

Despite these strengths, limitations must be noted. First, although the original HOPE subject population frequency matched cases and controls by 5-year age groupings, when restricting to women reporting at least one live birth, controls were significantly younger than cases (Table 1). Some of our findings, especially with respect to age and recency of breastfeeding, may reflect the structure of the restricted dataset. To address this, we repeated our analyses limiting subjects to women over 50 years of age, which showed similar results to analyses in the overall population.

Because of the large age range in our study population, we cannot eliminate the possible influence of cohort effects. We controlled for age in our models and our analyses restricting subjects to women 50+ years of age produced findings similar to those of the overall population. In addition, including a term for decade of birth (as a marker for cohorts) and analyses including a term for subject birth year pre-or post-1950 (as a more gross marker for cohorts) did not impact effect estimates.

As in all case-control studies, we cannot eliminate the possibility of recall bias. However, participants were not aware of the study hypotheses since questions regarding breastfeeding were collected as part of a more detailed interview regarding various aspects of reproductive health and behavior. In addition, trained interviewers used structured, standardized interview questions and prompts, including life event calendars, which provided graphical time frames to help improve respondents' long-term recall. Selection bias is also a concern. The population-based design and frequency-matching by three-digit telephone prefix, a marker of geographical location, increased the likelihood that controls were representative of the population from which the cases arose. However, we cannot exclude the possibility that controls who chose to participate in HOPE differed in important exposure or confounding factors from potential controls who did not, thereby over- or under-estimating the true association. The lack of information on lactational amenorrhea, exclusive breastfeeding, and effects of breastfeeding on maternal anthropometry are also limitations. Finally, because more than 97% of controls and 94% of cases were white women from western PA, eastern OH, and southwestern NY, the generalizability of our findings to other races or ethnicities cannot be assumed.

Approximately 82% of U.S. women give birth to at least one child.<sup>33</sup> The American Academy of Pediatrics (AAP) recommends exclusive breastfeeding for 6 months and continued breastfeeding for at least 1 year.<sup>34</sup> The American College of Obstetricians and Gynecologists (ACOG) affirms this recommendation.<sup>35</sup> Despite these recommendations, less than 20% of infants are exclusively breastfed for 6 months, less than 50% are breastfed for 6 months, and only 27% are still breastfeeding at 1 year.<sup>36</sup> Our findings suggest that improving compliance with AAP and ACOG recommendations could impact EOC risk in the vast majority of U.S. women.

In conclusion, interventions to encourage and support women in breastfeeding may help reduce EOC risk. Breastfeeding any offspring for as little as 3 months imparts significant protection. Thus, encouraging women to breastfeed even if only during a maternity leave can provide benefit. Notably, this protection persists for more than 30 years and is similar to the magnitude and duration of protection associated with oral contraceptive use and bearing



children, the two well-established EOC protective factors. Studies examining the biological bases for the observations presented in this and other work examining the EOC-breastfeeding link can potentially shed light on EOC etiology and open pathways to identifying new prevention modalities, which are critical in overcoming this highly fatal malignancy.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

**Funding:** This work supported by National Cancer Institute (K07-CA80668, R01CA095023); the Department of Defense (DAMD17-02-1-0669); and the University of Pittsburgh School of Medicine Dean's Faculty Advancement Fund.

An early version of this work was presented at the AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, Pittsburgh, PA. October 2017.

## REFERENCES

1. American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018.
2. Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2012;157(12):900–4. [PubMed: 22964825]
3. Modugno F, Edwards RP. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. *Int J Gynecol Cancer.* 2012;22(8):S45–57. [PubMed: 23013733]
4. Cho KR, Shih Ie M. Ovarian cancer. *Annu Rev Pathol.* 2009;4:287–313. [PubMed: 18842102]
5. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. *Curr Opin Obstet Gynecol.* 2007;19(1):3–9. [PubMed: 17218844]
6. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet.* 2008;371(9609):303–14. [PubMed: 18294997]
7. Sung HK, Ma SH, Choi JY, et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: A systematic review and meta-analysis. *J Prev Med Public Health.* 2016;49(6):349–66. [PubMed: 27951628]
8. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. *Am J Epidemiol.* 2008;167(9):1059–69. [PubMed: 18303003]
9. Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? *Lancet.* 1971;2(7716):163. [PubMed: 4104488]
10. Bahar-Shany K, Brand H, Sapoznik S, et al. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. *Gynecol Oncol.* 2014;132(2):322–7. [PubMed: 24355484]
11. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. *J Natl Cancer Inst.* 1983;71(4):717–21. [PubMed: 6578367]
12. George SH, Milea A, Shaw PA. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. *Clin Cancer Res.* 2012;18(22):6199–207. [PubMed: 22967960]
13. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response in ovarian cancer: time to reconsider as a clinical target? *Endocr Relat Cancer.* 2012;19(6):R255–79. [PubMed: 23045324]
14. McNeilly AS. Lactational control of reproduction. *Reprod Fertil Dev.* 2001;13(7–8):583–90. [PubMed: 11999309]

15. Li DP, Du C, Zhang ZM, et al. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. *Asian Pac J Cancer Prev*. 2014;15(12):4829–37. [PubMed: 24998548]
16. Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang YL, Lin B. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. *Am J Clin Nutr*. 2013;98(4):1020–31. [PubMed: 23966430]
17. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. Breastfeeding and risk of ovarian cancer in two prospective cohorts. *Cancer Causes Control*. 2007;18(5):517–23. [PubMed: 17450440]
18. Lo-Ciganic WH, Zgibor JC, Bunker CH, A KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. *Epidemiology*. 2012;23(2):311–9. [PubMed: 22252409]
19. Freedman D, Thornton A, Camburn D, Alwin D, Young-demarco L. The life history calendar: a technique for collecting retrospective data. *Sociol Methodol*. 1988;18:37–68. [PubMed: 12282712]
20. Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Int J Epidemiol*. 1993;22(2):192–7. [PubMed: 8505173]
21. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. *Ann Epidemiol*. 2001;11(8):568–74. [PubMed: 11709277]
22. Titus-Ernstoff L, Rees JR, Terry KL, Cramer DW. Breast-feeding the last born child and risk of ovarian cancer. *Cancer Causes Control*. 2010;21(2):201–7. [PubMed: 19902367]
23. Jordan SJ, Siskind V, A CG, Whiteman DC, Webb PM. Breastfeeding and risk of epithelial ovarian cancer. *Cancer Causes Control*. 2010;21(1):109–16. [PubMed: 19779839]
24. Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. *Obstet Gynecol*. 2013;122(1):139–47. [PubMed: 23743450]
25. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2003;12(1):42–6. [PubMed: 12540502]
26. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. *Lancet*. 1994;344(8932):1250–4. [PubMed: 7967985]
27. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. *Proc Natl Acad Sci U S A*. 2012;109(10):3921–6. [PubMed: 22331912]
28. Short RV, Lewis PR, Renfree MB, Shaw G. Contraceptive effects of extended lactational amenorrhoea: beyond the Bellagio Consensus. *Lancet*. 1991;337(8743):715–7. [PubMed: 1672186]
29. Zinaman MJ, Hughes V, Queenan JT, Labbok MH, Albertson B. Acute prolactin and oxytocin responses and milk yield to infant suckling and artificial methods of expression in lactating women. *Pediatrics*. 1992;89(3):437–40. [PubMed: 1741218]
30. Stuebe AM, Rich-Edwards JW. The reset hypothesis: lactation and maternal metabolism. *Am J Perinatol*. 2009;26(1):81–8. [PubMed: 19031350]
31. Otokozawa S, Tanaka R, Akasaka H, et al. Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study. *Asian Pac J Cancer Prev*. 2015;16(12):4987–91. [PubMed: 26163627]
32. Sun W, Lu J, Wu S, et al. Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. *Am J Cancer Res*. 2016;6(10):2334–44. [PubMed: 27822422]
33. Martinez G, Daniels K, Chandra A. Fertility of men and women aged 15–44 years in the United States: National Survey of Family Growth, 2006–2010. *Natl Health Stat Report*. 2012(51):1–28.
34. American Academy of Pediatrics. Breastfeeding and the use of human milk. *Pediatrics*. 2012;129(3):e827–41. [PubMed: 22371471]

35. American College of Obstetricians Committee Opinion No. 658: Optimizing Support for Breastfeeding as Part of Obstetric Practice. *Obstet Gynecol.* 2016;127(2):e86–92. [PubMed: 26942393]
36. CDC. Breastfeeding Among U.S. Children Born 2002–2014, CDC National Immunization Survey. 2018; <https://www.cdc.gov/breastfeeding/data/nisdata/index.htm>. Accessed August 24, 2018.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**HIGHLIGHTS**

Breastfeeding any offspring for as few as 3 months – the duration of a maternity leave - protects against ovarian cancer.

This protection decreases over time but persists for more than 30 years.

Longer duration, greater number of offspring nursed, and earlier age at first breastfeeding increase protection.

This protection is similar to the magnitude and duration of protection associated with oral contraceptive use and bearing children.

**Table 1.**

Characteristics of HOPE Study Participants, 2003–2008

	<b>Controls (N=1,572) N (%)</b>	<b>Cases (N=689) N (%)</b>	<b>P-Value</b>
<b>Age, years</b>			<0.001
<50	450(28.6)	133(19.3)	
50–54	211(13.4)	96 (13.9)	
55–59	279(17.8)	113(16.4)	
60–64	178(11.3)	93 (13.5)	
65–69	175(11.1)	83 (12.1)	
70+	279(17.8)	171(24.8)	
<b>Race</b>			0.001
White	1530 (97.3)	652(94.6)	
Black	27(1.7)	31(4.5)	
Other	15(1.0)	6 (0.9)	
<b>Education</b>			<0.001
Less than High School	75(4.8)	74 (10.7)	
High School	488(31.0)	249(36.1)	
Post High School Training	495(31.5)	191(27.7)	
College Graduate	514(32.7)	175(25.4)	
<b>Menopausal Status</b>			0.003
Pre-menopausal	481(30.6)	168(24.4)	
Post-menopausal	1039 (66.1)	505(73.3)	
Unknown	52(3.3)	16(2.3)	
<b>Body Mass Index (BMI), kg/m<sup>2</sup></b>			0.409
<25	595 (37.9)	243(35.3)	
25–29	466(29.7)	204(29.7)	
30	510(32.5)	241(35.0)	
<b>Oral Contraceptive use</b>			<0.001
Never	451(28.7)	271(39.3)	
Ever	1121 (71.3)	418(60.7)	
<b>Duration of Oral Contraceptive Use, years</b>			<0.001
0	451(28.7)	271(39.3)	
<1	247(15.7)	126(18.3)	
1–4	425(27.0)	156(22.6)	
5–9	267(17.0)	94 (13.6)	
10+	182(11.6)	42(6.1)	
<b>Number of Full Births</b>			0.212
1	231(14.7)	120(17.4)	
2	601(38.2)	264(38.3)	
3+	740(47.1)	305(44.3)	
<b>Tubal Ligation</b>			<0.001

	<b>Controls (N=1,572) N (%)</b>	<b>Cases (N=689) N (%)</b>	<b>P-Value</b>
No	979(62.3)	496(72.0)	
Yes	593(37.7)	193(28.0)	
<b>Hysterectomy</b>			<b>0.002</b>
No	1284 (81.7)	523(75.9)	
Yes	288(18.3)	166(24.1)	
<b>Hormone Replacement Therapy Use</b>			<b>0.984</b>
Never	982(62.5)	432(62.7)	
Ever	540(34.4)	236(34.3)	
Unknown	50(3.2)	21(3.1)	
<b>Smoking Status</b>			<b>0.473</b>
Never Smoker	779(49.6)	340(49.4)	
Current Smoker	298(19.0)	118(17.1)	
Former Smoker	495(31.4)	231(33.5)	
<b>Family History of Breast or Ovarian Cancer</b>			<b>0.02</b>
No	1301 (82.9)	541(78.8)	
Yes	269(17.1)	146(21.3)	
<b>History of Endometriosis</b>			<b>0.318</b>
No	1465 (93.2)	634(92.0)	
Yes	107 (6.8)	55(8.0)	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2.** Association of Breastfeeding Patterns with Epithelial Ovarian Cancer, the HOPE Study 2003–2008

Factor	Controls N (%)	Cases N (%)	Odds Ratio	95% Confidence Interval	Adjusted Odds Ratio *	95% Confidence Interval
<b>Ever Breastfed</b>						
No	684 (43.5)	386(56.0)	1		1	
Yes	888 (56.5)	303(44.0)	0.6	0.50–0.72	0.70	0.58–0.85
<b>Breastfed All Offspring</b>						
Never Breastfed	684 (43.5)	386(56.0)	1		1	
Breastfed some, but not all	328 (20.9)	119(17.3)	0.64	0.50–0.82	0.69	0.53–0.89
Breastfed All	560 (35.6)	184(26.7)	0.58	0.47–0.72	0.71	0.57–0.89
<b>Breastfed First Offspring</b>						
Never Breastfed	684 (43.5)	386(56.0)	1		1	
Breastfed some, but not first	122 (7.8)	46(6.7)	0.67	0.47–0.96	0.77	0.52–1.11
Breastfed First Offspring	766 (48.7)	257(37.3)	0.59	0.49–0.72	0.69	0.57–0.85
<b>Breastfed Last Offspring</b>						
Never Breastfed	684 (43.5)	386(56.0)	1		1	
Breastfed some, but not last	198 (12.6)	71 (10.3)	0.64	0.47–0.86	0.65	0.47–0.89
Breastfed Last	690 (43.9)	232(33.7)	0.60	0.49–0.72	0.72	0.58–0.89
<b>Number of Breastfeeding Episodes</b>						
Never Breastfed	684 (43.5)	386(56.0)	1		1	
1 or 2 episodes	619 (39.4)	238(34.5)	0.68	0.56–0.83	0.78	0.64–0.96
3 or more episodes	269 (17.1)	65(9.4)	0.43	0.32–0.58	0.49	0.36–0.68

trend p=0.01

\* Separate models and analyses for each factor. Each model adjusted for age, race, education, duration of oral contraceptive use, and number of pregnancies.

**Table 3.**

Association of Breastfeeding Duration with Epithelial Ovarian Cancer, the HOPE Study 2003–2008

Factor	Controls N (%)	Cases N (%)	Odds Ratio	95% Confidence Interval	Adjusted Odds Ratio *	95% Confidence Interval
<b>Total Duration of Breastfeeding (years)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1		1	
<1	502 (31.9)	192 (27.9)	0.68	0.55–0.83	0.75	0.61–0.94
1 or more	386 (24.6)	110(16.0)	0.50	0.39–0.65	0.62	0.47–0.80
<b>Duration of Breastfeeding per breastfeeding episode (months)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1		1	
3	375 (23.9)	143 (20.8)	0.68	0.54–0.85	0.73	0.58–0.93
4 or more	513 (32.6)	159 (23.1)	0.55	0.44–0.60	0.67	0.53–0.85
<b>Duration of breastfeeding first breastfeeding episode (months)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1		1	
3	396 (25.2)	151 (21.9)	0.68	0.54–0.85	0.75	0.59–0.94
4 or more	492 (31.3)	151 (21.9)	0.54	0.44–0.68	0.66	0.52–0.84
<b>Duration of breastfeeding last breastfeeding episode (months)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1		1	
3	393 (25.0)	154 (22.4)	0.69	0.55–0.87	0.75	0.60–0.95
4 or more	495 (31.5)	148 (21.5)	0.53	0.42–0.66	0.65	0.51–0.83

\* Separate models and analyses for each factor. Each model adjusted for age, race, education, duration of oral contraceptive use, and number of pregnancies.



**Table 4.**  
Timing of Breastfeeding and Epithelial Ovarian Cancer, the HOPE Study 2003–2008

Factor	Controls N (%)	Cases N (%)	Odds Ratio	95% Confidence Interval	Adjusted Odds Ratio*	95% Confidence Interval
<b>Age at First Breastfeeding Episode (years)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1	1	1	
<25	415 (26.4)	141 (20.5)	0.60	0.48–0.76	0.63	0.50–0.80
25–29	295 (18.8)	91 (13.2)	0.55	0.42–0.71	0.71	0.54–0.95
30+	178 (11.3)	71 (10.3)	0.71	0.52–0.96	0.92	0.67–1.27
					trend	
					p=0.001	
<b>Age at Last Breastfeeding Episode (years)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1	1	1	
<25	199 (12.7)	75 (10.9)	0.67	0.50–0.90	0.66	0.49–0.89
25–29	246 (15.7)	90 (13.1)	0.65	0.49–0.85	0.76	0.57–1.00
30+	443 (28.2)	138 (20.0)	0.55	0.44–0.69	0.70	0.55–0.90
<b>Time Since First Breastfeeding Episode (years)</b>						
Never Breastfed	684 (43.5)	386 (56.0)	1	1	1	
<10	71 (4.5)	12 (1.7)	0.30	0.16–0.56	0.56	0.28–1.10
10–19	150(9.5)	41(5.9)	0.48	0.34–0.70	0.76	0.50–1.14
20–29	253(16.1)	92(13.4)	0.64	0.49–0.84	0.85	0.63–1.14
30+	414(26.3)	158 (22.9)	0.68	0.54–0.84	0.64	0.51–0.80
<b>Time Since Last Breastfeeding Episode (years)</b>						
Never Breastfed	684(43.5)	386 (56.0)	1	1	1	
<10	114(7.3)	21(3.1)	0.33	0.20–0.53	0.56	0.32–0.95
10–19	209(13.3)	58(8.4)	0.49	0.36–0.67	0.70	0.49–0.99
20–29	224(14.3)	82(11.9)	0.65	0.49–0.86	0.80	0.59–1.07
30+	341 (21.7)	142 (20.6)	0.74	0.59–0.93	0.69	0.53–0.88

\* Separate models and analyses for each factor. Each model adjusted for age, race, education, duration of oral contraceptive use, and number of pregnancies.